Huddart 2002.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 95, lung, gynecological, genitourinary, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 10000 IU sc TIW hb‐target = 12‐14 g/dL planned ESA duration = during chemotherapy
Outcomes	Hb response, reticulocyte, survival, QoL, safety
Notes	study number = 88443
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Unclear risk	no description